Yesterday I closed my post with this cryptic statement:

Did you happen to read the comment from Terry yesterday following my post slamming skeletal surveys?  Just in case you missed it…

I wanted to keep those of you who kindly follow my site updated on my medical journey.

Most of you probably know that I have been working on several new books about multiple myeloma. 

We learned a lot about salvage therapy a few days back.   Let’s continue our multiple myeloma education and study the ABCs of therapy for newly diagnosed patients.

One more review of last December’s ASH in San Diego.

A few days back I ran a post about how improvements in the way allogeneic transplants are administered may help reduce the number and severity of side-effects:

It was easy to become a bit discouraged as I wrote my book last year, Stem Cell Transplants from a Patient’s Perspective.

More odds and ends to share…

Nashville’s Fox 13 reporter, Lauren Johnson, filed this report about local multiple myeloma patient Jana Stressel yesterday.

I attended a Florida Educational Advocacy Group event last evening at Moffitt Cancer Center in Tampa.  The topic:  New Treatment Options for Multiple Myeloma.

One year ago, I wrote several articles about NBA Orlando Magic executive Pat Williams, and his unexpected multiple myeloma diagnosis:

After all of the deep and theoretical topics I have been writing about lately, it’s nice to concentrate on something a bit more positive and practical.

Amyloidosis is a close cousin to multiple myeloma.

Today is a proud day for me.  The first print run of my second book, Stem Cell Transplants from a Patient’s Perspective, has been shipped by the publisher.

I have been traveling/flying every ten days or so lately–and it’s taking a toll on my day to day health.

Last month I was featured in a Nature Magazine article about multiple myeloma and stem cell transplants:

If you had an 18% chanced of success, would you consider undergoing a second autologous stem cell transplant after the first transplant failed?

For every comment that shows-up on my site, I receive at least three or four emails.  Apparently, so does our new nutritional columnist, Danny Parker.

If your read Friday’s post about my emotional evening at the IMF’s International Jounalist event last week, you will probably recall how my roller-coaster “crashed down” after hearing about an unexpectedly short, 8 month overall survival (OS) benefit from using pomalidomid and dexamethasone after patients became refractory to Revlimid and Velcade.